Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02173119 · ClinicalTrials.gov registry record
Can Quantitative MRI After cTACE Help Predict Survival ?
A clinical trial, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- 23
- Enrollment target
NCT02173119: Completed study, sponsored by Medical College of Wisconsin.
NCT02173119 is a clinical trial that has completed, run by Medical College of Wisconsin. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02173119 has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
Transcatheter arterial chemoembolization (TACE) is a widely accepted palliative therapy for the treatment of HCC. Palliative means that it does not cure the disease prolongs your life and improves quality of life. During TACE, a mixture of chemotherapy drugs is combined with an oil called lipiodol. Lipiodol has a role as both drug carrier and embolic agent (a material that blocks blood flow to tumors). The lipiodol/chemotherapy mixture is injected into an artery (blood vessel) directly supplying blood to a HCC tumor. Lipiodol is made up of fat and water which can be seen on MRI. Therefore, MRI can be used to quantify the amount of lipiodol delivered to the HCC tumors. In this study, the investigators want to see if patient survival is related to the amount of lipiodol delivered to HCC tumors.
Primary Outcome
Imaging response will be assessed according to 3D European Association for the Study of the Liver (EASL) criteria. EASL criteria propose using contrast enhanced (CE) images to measure viable volumes. We will transfer all images to a computer workstation. We will measure 'viable' enhancing tumor volumes at each interval and percent change in viable tumor volume (change from baseline). We will correlate lipiodol delivery measurements to primary outcomes post-therapy.
Interventions
- OTHER MRI post-TACE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-08 |
| Est. Completion | 2018-03-07 |
What the finished NCT02173119 record still lists
NCT02173119 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which MRI post-TACE is the first listed.
NCT02173119 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02173119 about?
NCT02173119 is a clinical study titled "Can Quantitative MRI After cTACE Help Predict Survival ?". Transcatheter arterial chemoembolization (TACE) is a widely accepted palliative therapy for the treatment of HCC. Palliative means that it does not cure the disease prolongs your life and improves quality of life. During TACE, a mixture of chemotherapy drugs is combined with an oil called lipiodol. ...
What is the current status of trial NCT02173119?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2014-08. Estimated completion is 2018-03-07.
What interventions are being tested in trial NCT02173119?
The interventions under investigation include: MRI post-TACE (OTHER).
Who is sponsoring clinical trial NCT02173119?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia